索菲布韦联合利巴韦林治疗2a型丙型肝炎肝硬化代偿期患者临床观察  

Efficacy of sofosbuvir and ribavirin for HCV genotype 2a with compensated cirrhosis

作　　者：周坤[1] 张宁[1] 张帆[1] 白云峰[1] 王仲霞[1] 何婷婷[1] 王葽[1] 周超[1] 宫嫚[1] ZHOU Kun ZHANG Ning GONG Man et al(center of liver disease combining traditional Chinese and Western Medicine of 302 Hospital of PLA （ Beijing, 100039） China)

机构地区：[1]中国人民解放军第302医院中西医结合肝病中心,北京100039

出　　处：《中西医结合肝病杂志》2017年第3期132-133,143,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：国家中医药管理局国家中医临床研究基地业务建设科研项目基金(No.JDZX2015187);解放军302医院院内课题(No.YNKT2013027)

摘　　要：目的:探讨索菲布韦联合利巴韦林治疗丙型肝炎肝硬化的临床效果。方法:回顾性分析我科自2014年5月-2015年5月收治的40例2a型丙型肝炎肝硬化代偿期患者,其中20例患者使用索菲布韦联合利巴韦林(DAAs组)治疗;20例患者使用聚乙二醇干扰素α-2a(派罗欣)联合利巴韦林(干扰素组)治疗,观察两组患者临床疗效及药物副作用。结果:①DAAs组患者7天病毒应答率、快速应答(RVR)率、完全应答(ETR)率、持续应答(SVR)率与干扰素组相比明显升高,差异有统计学意义(P<0.05);②治疗过程中,DAAs组患者不良反应(头痛、发热、肌肉关节痛、抑郁及血小板、白细胞减少)发生率明显低于干扰素组,差异有统计学意义(P<0.05)。结论:DAAs组患者的临床疗效明显高于干扰素组,且不良反应发生率明显低于干扰素组,索菲布韦联合利巴韦林是治疗丙型肝炎肝硬化代偿期患者有效、安全的药物。Objective： To evaluated the clinical efficacy of sofosbuvir and ribavirin for HCV genotype 2a with compensated cirrhosis. Meth- ods ： A retrospective analysis of forty inpatients diagnosed as compensated cirrhosis with hepatitis C genotpye 2a in the integrative department of the 302 hospital of PLA from May 2014 to May 2015. Totally 40 patients were enrolled including 20 in the experimental group and 20 in the control group, respectively. In the experimental group, patients received the treatment of sofosbuvir and ribavirin, while in the control group patients were treated by pegylated interferon （Pegasys） and ribavirln. The clinical efficacy and side effects were evaluated between these two groups. Results： （ 1 ） Patients in the experimental group achieved significantly higher rates in virological response after 7 days treatment, rapid virological response （RVR） , end of treatment response （ETR） and sustained virological response （SVR） compared to the control group （P 〈 0.05）. （2） The incidence of adverse events（headache, fever, muscle and joint pain, depression, thrombocytopenia, leukopenia, etc. ）in the experimental group were lower than that in the control group during the period of treatment （ P 〈 0.05 ）. Conclusion： The clinical efficacy of sofosbuvir and ribavirin was remarkably better and the incidence of adverse events of that was significantly lower than the treatment of inter- feron and ribavirin in compensated cirrhotic patients with HCV genotype 2a infection. Sofosbuvir and ribavirin combination therapy is an effec- tive and safe treatment for compensated cirrhotic patients with HCV genotype 2a infection.

关 键 词：索菲布韦 利巴韦林 聚乙二醇干扰素 肝炎 丙型 肝硬化代偿期 临床疗效 

分 类 号：R512.63[医药卫生—内科学] R575.2[医药卫生—临床医学]